A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation

Journal of Neurology

Volumn 258, Issue 4, 2011, Pages 579-585

  Antonini, Angelo ^a,b,c   Isaias, Ioannis U ^a,d   Rodolfi, Giorgia ^a   Landi, Andrea ^e   Natuzzi, Francesca ^a   Siri, Chiara ^a   Pezzoli, Gianni ^a  

^a PARKINSON INSTITUTE   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

Author keywords

Apomorphine; Deep brain stimulation; Parkinson disease

Indexed keywords

APOMORPHINE; LEVODOPA;

ADULT; AGED; ANTIBIOTIC THERAPY; APATHY; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; DEATH; DEVICE INFECTION; DEVICE REMOVAL; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PANNICULITIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN NODULE; SKIN ULCER; SOMNOLENCE; SUBCUTANEOUS NODULE; SUBTHALAMIC NUCLEUS; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; DEEP BRAIN STIMULATION; FEMALE; HUMANS; INFUSIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SUBTHALAMIC NUCLEUS;

EID: 79953806050     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5793-z     Document Type: Article

References (42)

1. Antonini A (2007) New strategies in motor parkinsonism. Parkinsonism Relat Disord 13:446-449
2. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, CSP 468 Study Group et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63-73
3. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, German Parkinson Study Group, Neurostimulation Section et al (2006) A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355:896-908 (Pubitemid 44315982)
4. Deleu D, Hanssens Y, Northway MG (2004) Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 21:687-709 (Pubitemid 39273964)
5. García Ruiz PJ, Sesar Ignacio A, Ares Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 23:1130-1136
6. Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 9:859-867
7. De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F et al (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 77:450-453
8. Defer GL, Widner H, Marié RM, Rémy P, Levivier M (1999) Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 14:572-584 (Pubitemid 30011449)
9. Lang AE, Widner H (2002) Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 17:94-101
10. Grosset KA, Grosset DG (2006) Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's disease. Clin Ther 28:1063-1064
11. Vergani F, Landi A, Antonini A, Parolin M, Cilia R, Grimaldi M et al (2007) Anatomical identification of active contacts in subthalamic deep brain stimulation. Surg Neurol 67:140-146 (Pubitemid 46123490)
12. Isaias I, Tagliati M (2007) Deep brain stimulation programming for movement disorders. In: Tarsy D, Okun M, Starr P, Vitek J (eds) DBS in neurological and psychiatric disorders. Humana Press, New York
13. Friston KJ, Grasby PM, Bench CJ, Frith CD, Cowen PJ, Liddle PF et al (1992) Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci Lett 141:106-110
14. Montoya A, Lal S, Menear M, Duplessis E, Thavundayil J, Schmitz N, Lepage M (2008) Apomorphine effects on episodic memory in young healthy volunteers. Neuropsychologia 46:292-300
15. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ (1998) Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 50:573-574 (Pubitemid 28119827)
16. Nutt JG, Carter JH (2000) Apomorphine can sustain the long-duration response to L-dopa in fluctuating PD. Neurology 54:247-250 (Pubitemid 30038774)
17. Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 17:1235-1241 (Pubitemid 36041337)
18. Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ (2004) A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol 251:1370-1374
19. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 20:151-157 (Pubitemid 40361117)
20. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 22:93-94 (Pubitemid 32622278)
21. Kanovský P, Kubová D, Bares M, Hortová H, Streitová H, Rektor I, Znojil V (2002) Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 17:188-191 (Pubitemid 36041277)
22. Voon V, Kubu C, Krack P, Houeto JL, Tröster AI (2006) Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 21:305-327
23. Contarino MF, Daniele A, Sibilia AH, Romito LM, Bentivoglio AR, Gainotti G, Albanese A (2007) Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 78:248-252 (Pubitemid 46579660)
24. Castelli L, Lanotte M, Zibetti M, Caglio M, Rizzi L, Ducati A et al (2007) Apathy and verbal fluency in STN stimulated PD patients. An observational follow-up study. J Neurol 254:1238-1243 (Pubitemid 350112353)
25. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO et al (2008) Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 7:605-614
26. Sudhyadhom A, Bova FJ, Foote KD, Rosado CA, Kirsch-Darrow L, Okun MS (2007) Limbic, associative, and motor territories within the targets for deep brain stimulation: potential clinical implications. Curr Neurol Neurosci Rep 7:278-289 (Pubitemid 47098449)
27. Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G (2008) Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 23:1420-1427
28. Simuni T, Sethi K (2008) Nonmotor manifestations of Parkinson's disease. Ann Neurol 64:65-80
29. McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson TJ, Fink J, Roger D (2008) Neuropsychiatric problems in Parkinson's disease: comparisons between self and caregiver report. Aging Ment Health 12:647-653
30. Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J et al (2008) Apathy following subthalamic stimulation in Parkinson disease: a dopa- mine responsive symptom. Mov Disord 23:964-969
31. Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J et al (2010) Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 133:1111-1127
32. Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S et al (2009) Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 73:1746-1751
33. Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V (2006) Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord 12:265-272 (Pubitemid 43816341)
34. Ellis C, Lemmens G, Parkes JD, Abbott RJ, Pye IF, Leigh PN, Chaudhuri KR (1997) Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 3:103-107 (Pubitemid 28090190)
35. Stibe CM, Lees AJ, Kempster PA, Stern GM (1998) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1:403-406
36. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423-428 (Pubitemid 30248740)
37. Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F et al (2003) Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci 24:174-175 (Pubitemid 37304299)
38. Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F et al (2004) Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr 38:291-296 (Pubitemid 38822878)
39. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Tröster AI (2006) Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 5:578-588 (Pubitemid 43867425)
40. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H et al (2004) Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 75:834-839 (Pubitemid 38658504)
41. Kalbe E, Voges J, Weber T, Haarer M, Baudrexel S, Klein JC et al (2009) Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. Neurology 72:42-49
42. Cilia R, Marotta G, Landi A, Isaias IU, Mariani CB, Vergani F et al (2009) Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case control study. Clin Neurol Neurosurg 111:140-146